Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary) ; Durvalumab (Primary) ; Panitumumab (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms UNICORN
Most Recent Events
- 11 Jun 2025 Planned number of patients changed from 112 to 140.
- 26 Feb 2025 According to an Agenus media release, data from the study is presented at ASCO GI 2025
- 13 Feb 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.